CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

By Reuters News

Oct 24 (Reuters) - Johnson & Johnson JNJ.N on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial.

J&J had gained access to the drug through its $3.05 billion deal to buy Halda Therapeutics last year.



Here are more details:

  • The company was testing JNJ-6143 in patients with advanced prostate cancer who had received multiple treatments

  • Its novel approach selectively kills cancer cells by interfering with a protein they need to survive

  • In the trial, 77% of 31 evaluable patients receiving the 50-milligram dose saw their PSA levels, a blood marker used to monitor prostate cancer, fall by at least 50%; in 48% of patients, PSA levels fell by at least 90%

  • Among patients whose tumors could be measured using imaging, 69% had a confirmed complete or partial response

  • "It adds a new mechanism of action to J&J's prostate cancer portfolio," a Johnson & Johnson spokesperson said

  • Common side effects were nausea and elevated cholesterol and triglyceride levels. One patient discontinued treatment due to adverse effects

  • The data were presented at the European Society for Medical Oncology Congress


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.